<DOC>
	<DOCNO>NCT01937026</DOCNO>
	<brief_summary>The purpose study assess body handle baricitinib give another drug call probenecid . The study doctor measure amount baricitinib absorb blood stream time take remove baricitinib body . The safety tolerability drug study . The study last 18 day first dose end study ( include screen . )</brief_summary>
	<brief_title>A Study Baricitinib Probenecid Healthy Participants</brief_title>
	<detailed_description />
	<mesh_term>Probenecid</mesh_term>
	<criteria>Male participant : agree use 2 reliable method birth control female partner childbearing potential study least 3 month follow last dose study drug Female participant : woman childbearing potential due surgical sterilization confirm medical history menopause Have body mass index 18.0 29.0 kilogram per meter square ( kg/m^2 ) , inclusive Have clinical laboratory test result within normal reference range Have normal renal function Have normal blood pressure pulse rate Are currently enrol clinical trial concurrently enrol type medical research Have complete discontinue within last 90 day clinical trial involve study drug Are participants previously complete withdrawn study study investigate baricitinib , previously receive baricitinib Have know allergy baricitinib , probenecid , related compound , component baricitinib probenecid formulation , history significant atopy Have abnormality 12lead electrocardiogram ( ECG ) Have history current cardiovascular , respiratory , hepatic , renal , gastrointestinal , endocrine , hematological , neurological disorder capable significantly alter absorption , metabolism , elimination drug ; Have history current gout gouty arthritis Regularly use know drug abuse and/or show positive finding urinary drug screen Have current recent history clinically significant bacterial , fungal , parasitic , viral , mycobacterial infection Have symptomatic herpes zoster herpes simplex infection within 90 day prior first dose Show evidence human immunodeficiency virus ( HIV ) infection and/or positive human HIV antibody Show evidence hepatitis C infection and/or positive hepatitis C antibody Show evidence hepatitis B infection and/or positive hepatitis B surface antigen Are woman lactate Intend use overthecounter prescription medication ( include salicylate drug ) and/or herbal supplement within 14 day prior dose study intend use vitamin supplement first dose study drug discharge Clinical Research Unit ( CRU ) Have consume intend consume grapefruit grapefruitcontaining product within 7 day prior first dose throughout study Have use intend use drug substance know substrate , inhibitor , inducer organic anion transporter ( OAT ) 3 cytochrome P450 ( CYP ) 3A4 Have donate lose blood 500 milliliter ( mL ) within last 3 month Have average weekly alcohol intake exceed 28 unit per week ( male ) 21 unit per week ( female ) , unwilling stop alcohol consumption 48 hour prior first dose discharge CRU end study History , opinion investigator , excessive methylxanthine use within previous 6 month , great ( &gt; ) 6 cup coffee ( equivalent ) per day Currently smoke 10 cigarette per day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>